156 related articles for article (PubMed ID: 29411309)
1. HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs).
La Manna G
J Nephrol; 2018 Apr; 31(2):185-187. PubMed ID: 29411309
[No Abstract] [Full Text] [Related]
2. [Application of direct antiviral drugs in special patients with HCV infection].
Jiang C; Liu CY; Shao S; Gao YH
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):316-320. PubMed ID: 29996347
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C-Positive Kidney Transplant Recipients-When Is The Best Time to Treat With Direct-Acting Antiviral Agents?
Singh N; Dies D; Samant H
Transplantation; 2017 May; 101(5):e192. PubMed ID: 28437390
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents.
Lubetzky M; Chun S; Joelson A; Coco M; Kamal L; Ajaimy M; Gaglio P; Akalin E; De Boccardo G
Transplantation; 2017 Jul; 101(7):1704-1710. PubMed ID: 28009781
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
[TBL] [Abstract][Full Text] [Related]
6. Management and treatment of the HCV-infected kidney transplant patient.
Wong T; Bloom RD
Semin Dial; 2019 Mar; 32(2):169-178. PubMed ID: 30536995
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C in potential kidney and heart transplant patients.
Fabrizi F; Bunnapradist S; Martin P
Clin Liver Dis; 2005 Aug; 9(3):487-503, viii. PubMed ID: 16023979
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection in end-stage renal disease and kidney transplantation.
Burra P; Rodríguez-Castro KI; Marchini F; Bonfante L; Furian L; Ferrarese A; Zanetto A; Germani G; Russo FP; Senzolo M
Transpl Int; 2014 Sep; 27(9):877-91. PubMed ID: 24853721
[TBL] [Abstract][Full Text] [Related]
9. Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era.
Schaubel DE; Tran AH; Abt PL; Potluri VS; Goldberg DS; Reese PP
JAMA; 2022 Sep; 328(11):1102-1104. PubMed ID: 35994263
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials: Treatment of HCV-infected patients with advanced kidney disease.
Ladino M; Roth D
Nat Rev Nephrol; 2018 Jan; 14(1):6-8. PubMed ID: 29176656
[No Abstract] [Full Text] [Related]
11. Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.
Naggie S; Muir AJ
Annu Rev Med; 2017 Jan; 68():345-358. PubMed ID: 27686017
[TBL] [Abstract][Full Text] [Related]
12. Management of hepatitis C infection among patients with renal failure.
Latt NL; Araz F; Alachkar N; Durand CM; Gurakar A
Minerva Gastroenterol Dietol; 2015 Mar; 61(1):39-49. PubMed ID: 25390288
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C in Patients With RenalDisease: A Deeper Dive Into the KDIGO Guideline.
Terrault NA
Hepatology; 2018 Nov; 68(5):2035-2038. PubMed ID: 29672896
[No Abstract] [Full Text] [Related]
14. [Treatment in chronic renal failure].
Curciarello J; Fernández JL; Silva M
Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S55-7. PubMed ID: 20214305
[No Abstract] [Full Text] [Related]
15. Direct-acting agents for hepatitis C virus before and after liver transplantation.
Sugawara Y; Hibi T
Biosci Trends; 2018 Jan; 11(6):606-611. PubMed ID: 29238003
[TBL] [Abstract][Full Text] [Related]
16. [Hepatitis C infections in dialyzed patients].
Podlasin RB
Przegl Epidemiol; 2005; 59(2):541-7. PubMed ID: 16190565
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
Pol S; Parlati L
Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
[TBL] [Abstract][Full Text] [Related]
18. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease.
Kwo PY; Badshah MB
Curr Opin Organ Transplant; 2015 Jun; 20(3):235-41. PubMed ID: 25944238
[TBL] [Abstract][Full Text] [Related]
19. Successful heart-kidney transplantation from a Hepatitis C viremic donor to negative recipient: One year of follow-up.
Wettersten N; Tran H; Mekeel K; Pretorius V; Adler E; Aslam S
Transpl Infect Dis; 2019 Feb; 21(1):e13002. PubMed ID: 30222242
[TBL] [Abstract][Full Text] [Related]
20. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?
Trotter PB; Summers DM; Ushiro-Lumb I; Robb M; Bradley JA; Powell J; Watson CJE; Neuberger J
Transplantation; 2018 Apr; 102(4):664-672. PubMed ID: 29166338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
